Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Janssen’s daratumumab accepted for treatment of European patients with heavily pre-treated multiple myeloma
September 26, 2015 Off

Janssen’s daratumumab accepted for treatment of European patients with heavily pre-treated multiple myeloma

By Dino Mustafić

Janssen-Cilag International NV has announced on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European…

Recall of Murfy Farm’s alfalfa hay
September 25, 2015 Off

Recall of Murfy Farm’s alfalfa hay

By Dino Mustafić

Murphy Farm Hay and Feed Company of Louisburg North Carolina have initiated a voluntary limited recall of alfalfa hay due to…

September 25, 2015 Off

Tresiba and Ryzodeg get FDA’s approval

By Dino Mustafić

The U.S. Food and Drug Administration has approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to…

Johnson & Johnson completes divestiture of Splenda Brand to Heartland Food Products Group.
September 25, 2015 Off

Johnson & Johnson completes divestiture of Splenda Brand to Heartland Food Products Group.

By Dino Mustafić

Johnson & Johnson Consumer Inc. has completed the divestiture of Splenda Brand to Heartland Food Products Group. Johnson & Johnson announced…

CHMP reccomends Bayer’s Eye medicine for approval in EU
September 25, 2015 Off

CHMP reccomends Bayer’s Eye medicine for approval in EU

By Dino Mustafić

The European Committee for Medicinal Products for Human Use (CHMP) has recommended Bayer’s aflibercept solution for injection into the eye…

Bayer: Factor Xa inhibitor Xarelto approved in Japan
September 25, 2015 Off

Bayer: Factor Xa inhibitor Xarelto approved in Japan

By Dino Mustafić

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved in Japan Bayer’s oral Factor Xa inhibitor Xarelto (rivaroxaban) for the treatment…

Novartis: New NIBR director named. Entresto closer to be available EU
September 25, 2015 Off

Novartis: New NIBR director named. Entresto closer to be available EU

By Dino Mustafić

Switzerland-based Novartis has today appointed Dr. James E. Bradner, physician-scientist from Dana-Farber Cancer Institute and Harvard Medical School, as President of the…

‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries
September 25, 2015 Off

‘Novartis Access’, a portfolio of affordable medicines to treat chronic diseases in lower-income countries

By Dino Mustafić

Novartis has announced the launch of Novartis Access, a portfolio of 15 medicines to treat chronic diseases in low- and…

NIh: Clomiphene shows better results than letrozole for unexplained infertility
September 23, 2015 Off

NIh: Clomiphene shows better results than letrozole for unexplained infertility

By Dino Mustafić

Treatment with clomiphene, a standard therapy for couples with unexplained infertility, results in more live births than treatment with a…

Phase 3 study of ABP 215 meets its endpoints
September 23, 2015 Off

Phase 3 study of ABP 215 meets its endpoints

By Dino Mustafić

Amgen and Allergan plc. announced on Wednesday that a Phase 3 study of biosimilar candidate ABP 215 met its primary…

Posts pagination

Previous 1 … 6,288 6,289 6,290 … 6,292 Next

Popular posts

Medicago, GSK report primary and secondary endpoints with available data met in trial dominated by COVID-19 variants

December 10, 2021 Off

Repare Announces Completion of Acquisition by XenoTherapeutics, Inc.

January 29, 2026 Off
Cosentyx meets the primary endpoints

Cosentyx meets the primary endpoints

June 15, 2015 Off
Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

Adapt Pharma rolls submision to NDA for naloxone-based nasal spray

June 15, 2015 Off
Strensiq in HPP patiens therapy get approval from European Commission

Strensiq in HPP patiens therapy get approval from European Commission

September 13, 2015 Off

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine